Threshold Pharmaceuticals Inc. (NASDAQ:THLD) has received a consensus rating of “Hold” from the five ratings firms that are covering the stock. Three research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $0.52.
A number of equities analysts have recently issued reports on the company. William Blair restated an “outperform” rating on shares of Threshold Pharmaceuticals in a research note on Monday, October 3rd. S&P Equity Research dropped their price target on Threshold Pharmaceuticals from $0.67 to $0.52 in a research note on Friday, September 30th.
Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.55 on Tuesday. The stock has a market capitalization of $39.33 million, a PE ratio of 0.93 and a beta of 3.97. The stock has a 50 day moving average price of $1.04 and a 200-day moving average price of $0.62. Threshold Pharmaceuticals has a 12-month low of $0.21 and a 12-month high of $4.44.
Threshold Pharmaceuticals (NASDAQ:THLD) last released its quarterly earnings results on Monday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.10). On average, equities analysts anticipate that Threshold Pharmaceuticals will post ($0.38) earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Paloma Partners Management Co bought a new position in Threshold Pharmaceuticals during the second quarter valued at $152,000. Deerfield Management Co. bought a new position in Threshold Pharmaceuticals during the second quarter valued at $1,641,000. First Eagle Investment Management LLC bought a new position in Threshold Pharmaceuticals during the second quarter valued at $2,033,000. Oxford Asset Management increased its position in Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 178,602 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its position in Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock valued at $1,610,000 after buying an additional 500,000 shares during the period. Institutional investors own 28.22% of the company’s stock.
Threshold Pharmaceuticals Company Profile
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.